Rock Springs Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Rock Springs Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,483,468	Closed	-$595K	–	94
2025 Q2	$595K	Hold	2,483,468	–	–	0.04%	86
2025 Q1	$489K	Hold	2,483,468	–	–	0.03%	94
2024 Q4	$1.34M	Buy	2,483,468 +58,000	+2%	+$42.3K	0.05%	97
2024 Q3	$2.31M	Hold	2,425,468	–	–	0.08%	96
2024 Q2	$2.36M	Hold	2,425,468	–	–	0.07%	101
2024 Q1	$3.83M	Hold	2,425,468	–	–	0.1%	99
2023 Q4	$1.92M	Sell	2,425,468 -362,377	-13%	-$204K	0.05%	96
2023 Q3	$2.17M	Hold	2,787,845	–	–	0.06%	98
2023 Q2	$2.58M	Hold	2,787,845	–	–	0.06%	103
2023 Q1	$3.04M	Buy	2,787,845 +111,309	+4%	+$172K	0.07%	100
2022 Q4	$3.91M	Buy	2,676,536 +318,992	+14%	+$517K	0.09%	93
2022 Q3	$2.53M	Hold	2,357,544	–	–	0.07%	108
2022 Q2	$4.01M	Buy	2,357,544 +60,350	+3%	+$104K	0.12%	100
2022 Q1	$4.73M	Buy	2,297,194 +81,606	+4%	+$220K	0.12%	106
2021 Q4	$8.31M	Buy	2,215,588 +25,800	+1%	+$117K	0.19%	98
2021 Q3	$11.3M	Buy	2,189,788 +644,788	+42%	+$2.89M	0.24%	103
2021 Q2	$6.58M	Hold	1,545,000	–	–	0.13%	131
2021 Q1	$8.2M	Hold	1,545,000	–	–	0.18%	122
2020 Q4	$8.33M	Sell	1,545,000 -441,910	-22%	-$2.4M	0.18%	120
2020 Q3	$15.9M	Hold	1,986,910	–	–	0.4%	80
2020 Q2	$19.9M	Buy	1,986,910 +786,910	+66%	+$4.94M	0.55%	62
2020 Q1	$3.26M	Buy	1,200,000 +400,000	+50%	+$1.33M	0.14%	114
2019 Q4	$960K	Sell	800,000 -75,000	-9%	-$80K	0.03%	124
2019 Q3	$1.32M	Hold	875,000	–	–	0.05%	130
2019 Q2	$3.52M	Buy	875,000 +75,000	+9%	+$306K	0.13%	119
2019 Q1	$3.44M	Buy	800,000 +50,000	+7%	+$233K	0.13%	113
2018 Q4	$4.31M	Hold	750,000	–	–	0.2%	103
2018 Q3	$10.2M	Hold	750,000	–	–	0.37%	84
2018 Q2	$8.9M	Sell	750,000 -125,000	-14%	-$1.56M	0.34%	93
2018 Q1	$9.83M	Hold	875,000	–	–	0.42%	80
2017 Q4	$5.84M	Hold	875,000	–	–	0.27%	102
2017 Q3	$7.17M	Hold	875,000	–	–	0.33%	88
2017 Q2	$3.93M	Hold	875,000	–	–	0.2%	108
2017 Q1	$4.82M	Buy	875,000 +200,000	+30%	+$875K	0.28%	90
2016 Q4	$2.73M	Hold	675,000	–	–	0.18%	102
2016 Q3	$4.76M	Sell	675,000 -90,001	-12%	-$687K	0.3%	89
2016 Q2	$6.24M	Hold	765,001	–	–	0.46%	69
2016 Q1	$6.22M	Hold	765,001	–	–	0.52%	63
2015 Q4	$9.23M	Buy	765,001 +8,901	+1%	+$87.2K	0.7%	50
2015 Q3	$9.05M	Sell	756,100 -148,900	-16%	-$2.1M	0.73%	48
2015 Q2	$16.6M	Buy	+905,000	New	+$15.5M	1.21%	25

Other funds holding ADAP

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Rock Springs Capital Management's ADAP Position: Q3 2025 in Review

Rock Springs Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 2,483,468 shares — an estimated $595K sold.

Rock Springs Capital Management first reported a position in ADAP in Q2 2015 and held it in 41 quarters. The position peaked at $19.9M in Q2 2020. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

Rock Springs Capital Management reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
Rock Springs Capital Management sold 2,483,468 Adaptimmune Therapeutics shares in Q3 2025, an estimated $595K.
Rock Springs Capital Management first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 41 quarters.
Rock Springs Capital Management's Adaptimmune Therapeutics position peaked at $19.9M in Q2 2020.
55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on Rock Springs Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.